[A21-18] Beclometasone/formoterol/glycopyrronium (asthma) - Benefit assessment according to §35a Social Code Book V
Last updated 05.08.2021
Project no.:
A21-18
Commission:
Commission awarded on 11.02.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Airways and respiratory system
Adult patients with asthma whose disease is not adequately controlled with a combination of medium- or high-dose ICS and LABA, and who experienced one or more asthma exacerbations in the previous year
Medium-dose ICS/LABA therapy: added benefit not proven.
High-dose ICS/LABA therapy: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-85 | Beclometasone/formoterol/glycopyrronium (asthma) - Addendum to Commission A21-18 | Commission completed |
Federal Joint Committee (G-BA)
2021-08-05 A G-BA decision was published.